PATENT CLAIM ANALYSIS

Application Number: 16149522
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.

Claim (Index 31):
The use according to  claim 25 , wherein in Formula (I), (1) when X 2  is N, X 1  is N or CH, and (2) when X 2  is CH, X 1  is CH; 1 is 0 or 1; and (1) when Y is a group represented by Formula (A), the group represented by is azetidinylene, pyrrolidinylene, piperidinylene, piperazinylene, or morpholinylene, (2) when Y is a group represented by Formula (B), the group represented by is cyclopropylene or cyclobutylene, and (3) when Y is a group represented by Formula (C), the group represented by is phenylene.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.69231
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14905047', '13859569', '14344935', '15575448', '13617035']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7608236398547188
- 35 USC 102 Novelty (BERT): 0.6066933657325646
- Combined Prediction Score: 0.7454106124425034
- Mean Citation Score: 361.98346
- Max Citation Score: 551.84607
- Similarity Product: 450.3459873766208

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test